# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN
- Date: 2026-04-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eight-week review: blood pressure, lipids, kidney function, semaglutide and the endoscopy result. **S**

## History of present illness

Mr. Frazier returns six weeks after the consultation. He took semaglutide 0.25 mg weekly for four weeks and has taken 0.5 mg for two weeks; he had mild nausea for two days after each step and none now, and no abdominal pain. His appetite is smaller and he has lost 1.8 kg. He takes amlodipine 5 mg; home readings average 136/84. He has had no alcohol. The upper endoscopy last week showed no varices. He attended the first diabetes class. His eye appointment is next month. **S**

| Element | Detail |
|---|---|
| Semaglutide | 0.25 mg for four weeks, 0.5 mg for two weeks; mild nausea after each step, now gone |
| Home blood pressure | Average 136/84 on amlodipine 5 mg |
| Endoscopy | No varices |
| Alcohol | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Nausea after each dose step, now gone; no abdominal pain, vomiting or black stools |
| Cardiovascular | Negative | No ankle swelling or chest pain |
| Musculoskeletal | Negative | No muscle aches |

3 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/82 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 101.8 kg; BMI 30.7 kg/m². All vital signs are synthetic.

Potassium: 4.7 mmol/L; Creatinine: 1.1 mg/dL; eGFR (CKD-EPI 2021, no race term): 75 mL/min/1.73 m²; Total cholesterol: 148 mg/dL; LDL cholesterol: 68 mg/dL; HDL cholesterol: 40 mg/dL; Triglycerides: 168 mg/dL (high); AST: 44 U/L (high); ALT: 40 U/L. All results are synthetic.

## Change since baseline

- Potassium: 4.6 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Creatinine: 1.08 mg/dL at baseline, 1.1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021, no race term): 77 mL/min/1.73 m² at baseline, 75 mL/min/1.73 m² at this visit **S**
- Total cholesterol: 212 mg/dL (high) at baseline, 148 mg/dL at this visit **S**
- LDL cholesterol: 132 mg/dL (high) at baseline, 68 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 40 mg/dL at this visit **S**
- Triglycerides: 210 mg/dL (high) at baseline, 168 mg/dL (high) at this visit **S**
- AST: 48 U/L (high) at baseline, 44 U/L (high) at this visit **S**
- ALT: 42 U/L at baseline, 40 U/L at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 134/82, pulse 72; weight 101.8 kg |
| Cardiovascular | No ankle edema |
| Abdomen | Soft and non-tender; no ascites |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension** (I10). Improved but still above 130/80 in the clinic and at home. Potassium 4.7 and creatinine 1.10 mg/dL (eGFR 75), stable on lisinopril. **S**
   - Increase amlodipine to 10 mg daily.
   - Tell us about any ankle swelling.
2. **Hyperlipidemia on atorvastatin** (E78.5). LDL 68 mg/dL from 132 at eight weeks; AST 44 and ALT 40 U/L, not higher on the statin. **S**
   - Continue atorvastatin 40 mg; lipids yearly.
3. **Compensated cirrhosis from MASLD** (K74.69). No varices on endoscopy, so no beta-blocker is needed for that purpose; with the liver injury ongoing, the endoscopy should be repeated in two years. **S**
   - Repeat endoscopy in two years.
   - Second hepatitis B vaccine today.
   - Next surveillance ultrasound with AFP in September.
4. **Type 2 diabetes** (E11.65). Tolerating semaglutide; weight down 2.2 kg since intake. **S**
   - Continue semaglutide 0.5 mg weekly; consider 1 mg at the three-month visit.
   - A1c in five weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 134/82 in the clinic; home average 136/84; weight 101.8 kg |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2021) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Completed today | Potassium 4.7, creatinine 1.10 mg/dL, eGFR 75 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Completed today | Total 148, LDL 68, HDL 40, triglycerides 168 mg/dL |
| Laboratory | Liver tests with FIB-4 | With statin start and yearly | Completed today | AST 44, ALT 40 U/L |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Due | Due at three months, in five weeks |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 0.5 mg weekly; transient nausea; no abdominal pain |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Completed today | Endoscopy last week: no varices; repeat in two years |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Up to date | Baseline in March; next in September |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Ordered | Eye clinic appointment next month |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol |
| Self-management | Diabetes self-management education | At the start of care and yearly | Completed today | First class attended |
| Self-management | Vaccines for diabetes and chronic liver disease | At diagnosis of chronic liver disease | Completed today | Hepatitis B dose 2 today; hepatitis A dose 2 in September |

## Goal progress

- A1c below 7% within six to nine months, without low blood sugar. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home. In progress; target 2026-09-14. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-13: 132 to 68 mg/dL on atorvastatin. **S**
- Weight loss of 7 to 10% for liver health within a year. In progress; target 2026-09-14. **S**
- Liver cancer surveillance by ultrasound with AFP every six months, on time. In progress; target 2026-09-14. **S**
- No alcohol, to protect the liver. In progress; target 2026-09-14. **S**

## Medication changes

- Stopped: Amlodipine 5 mg oral tablet, one tablet daily **S**
- Started: Amlodipine 10 mg oral tablet, one tablet daily **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology 2023;78(6))
- Baveno VII - Renewing consensus in portal hypertension (2022), Baveno VII Faculty (Journal of Hepatology 2022;76(4))
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Three-month review in five weeks with the A1c and home readings. Eye clinic next month. **S**
- Next scheduled visit 2026-05-18: three-month review: A1c, blood pressure, weight, semaglutide dose and the eye examination. **S**
